Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 17-deacetylnorgestimate
2. 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, Oxime, (17alpha)-
3. Levonorgestrel Oxime
4. Levonorgestrel Oxime, (3e,17alpha)-isomer
5. Levonorgestrel Oxime, (3z,17alpha)-isomer
6. Lngo
7. Progestin Norelgestromin
1. Levonorgestrel Oxime
2. Norplant 3-oxime
3. D-norgestrel 3-oxime
4. 18-methylnorethindrone Oxime
5. 17-deacetylnorgestimate
6. 53016-31-2
7. 17-deacylnorgestimate
8. (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol
9. Deacetylnorgestimate
10. Norgestimate Metabolite Norelgestromin
11. Norelgestromin (17-deacetylnorgestimate)
12. Brn 4202099
13. Unii-r0tay3x631
14. Norelgestromin [usan:inn:ban]
15. Rwj 10553
16. Levonorgestrel 3-oxime
17. 17-deacetyl Norgestimate
18. 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, Oxime, (17alpha)-
19. R0tay3x631
20. Chembl4791392
21. Dtxsid9046788
22. 13-ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one Oxime
23. Db06713
24. 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, Oxime, (8-alpha,9-beta,10-alpha,13-alpha,14-beta)-
25. 17-deacylnorgestimate17-deacetyl Norgestimate
Molecular Weight | 327.5 g/mol |
---|---|
Molecular Formula | C21H29NO2 |
XLogP3 | 3.6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 2 |
Exact Mass | 327.219829168 g/mol |
Monoisotopic Mass | 327.219829168 g/mol |
Topological Polar Surface Area | 52.8 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 642 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 6 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 1 |
Covalently Bonded Unit Count | 1 |
Norelgestromin is used for contraception and menopausal hormonal therapy. Norelgestromin may potentially be used in breast cancer treatment due to its inhibitory effect on estrone sulfatase . They convert sulfated steroid precursors to estrogen during pregnancy.
Norelgestromin is used for contraception and menopausal hormonal therapy transdermally or in combination with ethinyl estradiol as a vaginal ring. Norelgestromin, in combination with ethinyl estradiol inhibits ovulation by suppressing gonadotropins.
Contraceptive Agents, Hormonal
Contraceptive agents that act on the ENDOCRINE SYSTEM. (See all compounds classified as Contraceptive Agents, Hormonal.)
G03AA13
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
Norelgestromin inhibits estrone sulfatase, which converts sulfated steroid precursors to estrogen during pregnancy. Norgelgestromin/ethinylestradiol suppresses follicular development, induces changes to the endometrium, which decreases chances of implantation and thickens the cervical mucus, impeding sperm swimming into the uterus. It also has similar agonisting binding affinities as its parent compound, Norgestimate, for progesterone and estrogen receptors.
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
42
PharmaCompass offers a list of Norelgestromin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Norelgestromin manufacturer or Norelgestromin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Norelgestromin manufacturer or Norelgestromin supplier.
PharmaCompass also assists you with knowing the Norelgestromin API Price utilized in the formulation of products. Norelgestromin API Price is not always fixed or binding as the Norelgestromin Price is obtained through a variety of data sources. The Norelgestromin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A ORTHO EVRA-1 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of ORTHO EVRA-1, including repackagers and relabelers. The FDA regulates ORTHO EVRA-1 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. ORTHO EVRA-1 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of ORTHO EVRA-1 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A ORTHO EVRA-1 supplier is an individual or a company that provides ORTHO EVRA-1 active pharmaceutical ingredient (API) or ORTHO EVRA-1 finished formulations upon request. The ORTHO EVRA-1 suppliers may include ORTHO EVRA-1 API manufacturers, exporters, distributors and traders.
click here to find a list of ORTHO EVRA-1 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A ORTHO EVRA-1 DMF (Drug Master File) is a document detailing the whole manufacturing process of ORTHO EVRA-1 active pharmaceutical ingredient (API) in detail. Different forms of ORTHO EVRA-1 DMFs exist exist since differing nations have different regulations, such as ORTHO EVRA-1 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A ORTHO EVRA-1 DMF submitted to regulatory agencies in the US is known as a USDMF. ORTHO EVRA-1 USDMF includes data on ORTHO EVRA-1's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The ORTHO EVRA-1 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of ORTHO EVRA-1 suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing ORTHO EVRA-1 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for ORTHO EVRA-1 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture ORTHO EVRA-1 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain ORTHO EVRA-1 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a ORTHO EVRA-1 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of ORTHO EVRA-1 suppliers with NDC on PharmaCompass.
ORTHO EVRA-1 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of ORTHO EVRA-1 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right ORTHO EVRA-1 GMP manufacturer or ORTHO EVRA-1 GMP API supplier for your needs.
A ORTHO EVRA-1 CoA (Certificate of Analysis) is a formal document that attests to ORTHO EVRA-1's compliance with ORTHO EVRA-1 specifications and serves as a tool for batch-level quality control.
ORTHO EVRA-1 CoA mostly includes findings from lab analyses of a specific batch. For each ORTHO EVRA-1 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
ORTHO EVRA-1 may be tested according to a variety of international standards, such as European Pharmacopoeia (ORTHO EVRA-1 EP), ORTHO EVRA-1 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (ORTHO EVRA-1 USP).